85 percent of African American adults expressed interest in genetic testing for AD susceptibility Alcohol dependence has a genetic component and testing may determine a person's genetic risk for susceptibility to Advertisement. A new study implies that while more than 85 percent of the African American adults expressed a pastime in genetic examining for AD susceptibility, many had ethical, privacy, and procedural concerns, as reported in Genetic Tests and Molecular Biomarkers, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.Food and Drug Administration granted priority review for the VIVITROL supplemental New Medication Application for opioid dependence. The FDA notified the company of the scheduling of a Psychopharmacologic Drugs Advisory Committee meeting on September 16, 2010, for the review of the business’s sNDA submission for VIVITROL for opioid dependence. ‘We reported another solid quarter as we plan our next growth phase with near-term opportunities to add additional sources of income,’ commented James Frates, Chief Financial Officer of Alkermes. ‘By the finish of calendar 2010, we anticipate a number of important milestones, including FDA action on both BYDUREON for the treatment of type 2 diabetes and VIVITROL for the treatment of opioid dependence, as well as an interim analysis from the phase 2 research of ALKS 33 for the treatment of alcohol dependence.june 30 ‘ Key operating outcomes for the quarter ended, 2010, include the following: GAAP net loss was $13.4 million or a simple and diluted loss per share of $0.14, including $4.5 million in share-based compensation expense.